Targeting mucus hypersecretion: new therapeutic opportunities for COPD? - Wikidata - awgldk - TriplyDB

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

http://www.wikidata.org/entity/Q38217069

about

Regeneration of the lung: Lung stem cells and the development of lung mimicking devices Role of Sphingolipids in the Pathobiology of Lung Inflammation Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections.Airway Epithelium Dysfunction in Cystic Fibrosis and COPD.Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases.Improved lung function and quality of life following guaifenesin treatment in a patient with chronic obstructive pulmonary disease (COPD): A case report.Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease.Improved quality of life associated with long-term use of guaifenesin in a patient with chronic obstructive pulmonary disease (COPD) & stable chronic bronchitis: A case report

P2860

Q26750856-9260392C-47CD-4E4A-A522-E7B181FC455D Q26771956-124F9C4B-C617-4069-8EA9-626B00A83443 Q27702643-19BFDA9E-6622-4189-99C4-A384F249C5F1 Q33857503-6D0526AD-E70A-4D05-B687-147C65FF5F91 Q38724563-CB1302D2-CE37-4D22-A2E6-05CF6C769B5A Q39030602-1E89B900-308D-4B9A-9692-88E708759CED Q47159691-08D48952-F140-413E-9EB1-C138051973A4 Q54970130-2BC3A1E0-7F23-49CF-81B3-F245F780CE5C Q55229995-4ED29B3D-2993-480E-92A4-82CC1D4BFB88 Q55423496-613E64B0-288B-4EAE-8469-0B54B8D69573 Q55440438-1EE660BF-F062-4BC8-8830-43B1977EB968 Q59132039-C216E699-2858-4214-92EA-AA4243561FAE

P2860

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

http://www.wikidata.org/entity/Q38217069

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

@en

type

label

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

@en

prefLabel

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

@en

P1433

Q38217069-03DDE966-0553-4ABA-B9FF-662C7F90D026

P1476

Q38217069-0F769AF2-2B50-416C-962F-DCB6A8B021CD

P2093

Q38217069-6CB0F198-D58A-4790-84F1-711ED6AA36AA

Q38217069-C88DA1F1-9909-482D-AFA2-335817D10349

Q38217069-CAC1A432-0D1E-4C33-9BB7-EF6202E537CD

P2860

Q38217069-07423916-FEE7-4351-A237-14172826C59A

Q38217069-0750E728-07E5-497E-B006-E375F360DF38

Q38217069-078278FA-2953-49BB-9417-84BCC1419A02

Q38217069-07FF197D-AD51-44AE-B3F2-349EFF0ACDA2

Q38217069-0876D6BA-52AD-4B6A-9E88-9FC55A7F3F83

Q38217069-08D27CCB-20F4-43AD-9F1E-026BDE8CFF1F

Q38217069-0D998AEE-E018-48C0-AE91-F9E76D1BD291

Q38217069-0EB33301-08ED-4852-8774-6BD0869A10AD

Q38217069-0F14ECA8-D31C-4AF0-99FD-82BEB6697404

Q38217069-0F31FCEA-35F2-4A16-92FF-C9A52530D7E0

P2888

Q38217069-75CD1C10-7241-48B1-8B42-CCD89ECE412C

P304

Q38217069-600B41C6-E9F1-4A16-8DF3-B9DC892B5C2C

P31

Q38217069-BBEF38E5-3393-49D5-8EBF-06AA0CEFA2A2

P356

Q38217069-E1D5B982-84B6-4B0A-A738-B51DF5151632

P433

Q38217069-842D0AE4-8129-4C8B-AB63-0CB02679E2E4

P478

Q38217069-6BAA1D61-B309-49DE-8EE8-80F364C1FDF0

P50

Q38217069-129897A4-A1D1-41A2-A0E7-E39A18AD66BE

Q38217069-4E18F111-A4A6-4DBC-B920-3FD30C14F6A0

Q38217069-C709BDE2-C486-434C-A378-B4902454CD62

P577

Q38217069-B82B5CD1-4EEB-487C-BE26-C7F923EC278F

P6179

Q38217069-1AE7A333-92B7-4926-9A89-090D0D1303E9

P698

Q38217069-EA152BD8-1583-446E-B2A2-E0B21142EB3C

P356

S40265-014-0235-3

P1433

P1476

Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

@en

P2093

Clémence Martin

http://www.w3.org/2001/XMLSchema#string

Justine Frija-Masson

http://www.w3.org/2001/XMLSchema#string

Pierre-Régis Burgel

http://www.w3.org/2001/XMLSchema#string

P2860

Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells

SPDEF regulates goblet cell hyperplasia in the airway epithelium

IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production

Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis.

MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro

Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells

Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells

MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005

Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils

Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats

P2888

s40265-014-0235-3

P304

1073-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0235-3

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Clémence Martin

Justine Frija-Masson

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007927865

http://www.w3.org/2001/XMLSchema#string

P698

24890395

http://www.w3.org/2001/XMLSchema#string